[HTML][HTML] Long-term effects, pathophysiological mechanisms, and risk factors of chemotherapy-induced peripheral neuropathies: a comprehensive literature review
N Kerckhove, A Collin, S Condé, C Chaleteix… - Frontiers in …, 2017 - frontiersin.org
Neurotoxic anticancer drugs, such as platinum-based anticancer drugs, taxanes, vinca
alkaloids, and proteasome/angiogenesis inhibitors are responsible for chemotherapy …
alkaloids, and proteasome/angiogenesis inhibitors are responsible for chemotherapy …
Chemotherapy‐induced peripheral neurotoxicity: a critical analysis
With a 3‐fold increase in the number of cancer survivors noted since the 1970s, there are
now over 28 million cancer survivors worldwide. Accordingly, there is a heightened …
now over 28 million cancer survivors worldwide. Accordingly, there is a heightened …
Chemotherapy-induced peripheral neurotoxicity (CIPN): an update
The peripheral nervous system can be vulnerable to the toxic action of several drugs since it
is not protected as effectively as the central nervous system from noxious exogenous agents …
is not protected as effectively as the central nervous system from noxious exogenous agents …
Chemotherapy‐induced neuropathy
AJ Windebank, W Grisold - Journal of the peripheral nervous …, 2008 - Wiley Online Library
Neurotoxic side effects of cancer therapy are second in frequency to hematological toxicity.
Unlike hematological side effects that can be treated with hematopoietic growth factors …
Unlike hematological side effects that can be treated with hematopoietic growth factors …
Chemotherapy-induced peripheral neurotoxicity
G Cavaletti, P Marmiroli - Nature Reviews Neurology, 2010 - nature.com
Chemotherapy-induced peripheral neurotoxicity (CIPN) is a common, potentially severe and
dose-limiting adverse effect of cancer treatment; however, the effects of CIPN on the daily life …
dose-limiting adverse effect of cancer treatment; however, the effects of CIPN on the daily life …
Management of treatment-emergent peripheral neuropathy in multiple myeloma
Peripheral neuropathy (PN) is one of the most important complications of multiple myeloma
(MM) treatment. PN can be caused by MM itself, either by the effects of the monoclonal …
(MM) treatment. PN can be caused by MM itself, either by the effects of the monoclonal …
The role of neuroinflammation in neuropathic pain: mechanisms and therapeutic targets
RR Myers, WM Campana, VI Shubayev - Drug discovery today, 2006 - Elsevier
Neuroinflammation is a proinflammatory cytokine-mediated process that can be provoked by
systemic tissue injury but it is most often associated with direct injury to the nervous system …
systemic tissue injury but it is most often associated with direct injury to the nervous system …
[HTML][HTML] Chemotherapy-induced peripheral neuropathy: an update on the current understanding
J Addington, M Freimer - F1000Research, 2016 - ncbi.nlm.nih.gov
Chemotherapy-induced peripheral neuropathy is a common side effect of selected
chemotherapeutic agents. Previous work has suggested that patients often under report the …
chemotherapeutic agents. Previous work has suggested that patients often under report the …
[HTML][HTML] Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations
B Mohty, J El-Cheikh, I Yakoub-Agha, P Moreau… - …, 2010 - ncbi.nlm.nih.gov
In multiple myeloma, peripheral neuropathy has for a long time been considered as mainly
secondary to the plasma cell dyscrasia itself. With the advent of new targeted drugs such as …
secondary to the plasma cell dyscrasia itself. With the advent of new targeted drugs such as …
Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring
L Mileshkin, R Stark, B Day, JF Seymour… - Journal of Clinical …, 2006 - ascopubs.org
Purpose Peripheral neuropathy frequently limits the duration of treatment with thalidomide
for patients with multiple myeloma. We assessed the time course of occurrence, possible …
for patients with multiple myeloma. We assessed the time course of occurrence, possible …